Journal profile · Biochemistry & Molecular Biology
Molecular Carcinogenesis
ISSN 0899-1987 · eISSN 1098-2744 · Wiley-Liss Inc. · UNITED STATES · Monthly · Founded 1988
Molecular Carcinogenesis: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 3.5; hybrid open access; APC about USD 4,490; median 124 days to acceptance (94 articles, last 24 months); community-reported acceptance: about 50%; 164 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Molecular Carcinogenesis is published by Wiley-Liss Inc. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cancer-related Molecular Pathways, RNA modifications and cancer and Epigenetics and DNA Methylation, together about 26.7% of its articles. Its main subfields are Molecular Biology and Cancer Research. (generated from OpenAlex topic counts and CAS ranking data)
Molecular Carcinogenesis publishes articles describing discoveries in basic, translational and clinical science of the mechanisms involved in genetic-, epigenetic-, chemical-, environmental-, physical (e.g., radiation, trauma)-, infection and immune dysregulation-associated cancer development, basic mechanisms of cancer prevention and therapy, and the development of biomarkers for cancer risk prediction, diagnosis and prognosis, and novel therapeutic targets and agents. Areas of interest include but are not limited to: Molecular and cellular mechanisms associated with normal homeostasis altered in neoplasia Molecular aspects of oncogenes, tumor suppressors, and their gene products in animal models and human cancer Epigenetic mechanisms related to cancer initiation, progression and therapy Microenvironment and systemic regulations in cancer initiation and progression Tumor immunology and immunotherapy Mechanisms of chemo-, dietary, and immuno- cancer prevention Molecular cancer epidemiology, populational science related to cancer etiology, disparities, therapeutic responses Biomarker discoveries for cancer risk, diagnosis, prognosis and therapeutic response Mechanisms of developmental and approved cancer therapeutics and clinical trials (targeted-, immuno-, chemo-, radio-therapy) with clear molecular/cellular targets Biostatistics, bioinformatics and computational approaches for the aforementioned areas Areas outside the scope of the journal include (transfer to Wiley’s other journals): Studies with no relevance to cancer Reporting genetic variants without functional validation Data mining from published data or publically available database without experimental validations Randomized clinical trials without a molecular target Research in a cell-free system or a single cell line Readership Readers interested in gaining knowledge of research related to cancer biology, cancer etiology and prevention, cancer genetics, cancer biomarkers, molecular and/or imaging diagnosis and therapeutic interventions
From the journal's Aims & Scope
Research area (LetPub): Biochemistry & Molecular Biology
Editor-in-chief Xiao-Jing WangPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer-related Molecular PathwaysMedicine11.3%
- RNA modifications and cancerBiochemistry, Genetics and Molecular Biology7.9%
- Epigenetics and DNA MethylationBiochemistry, Genetics and Molecular Biology7.5%
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology5.9%
- DNA Repair MechanismsBiochemistry, Genetics and Molecular Biology5.6%
- Cancer-related gene regulationBiochemistry, Genetics and Molecular Biology4.6%
- Cancer, Hypoxia, and MetabolismBiochemistry, Genetics and Molecular Biology4.4%
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology4.4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Biochemistry & Molecular Biology | Zone 3 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Biochemistry & Molecular Biology | Zone 3 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Biochemistry & Molecular Biology | Zone 2 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.5LetPub ·
- Impact factor (publisher)
- 3.5Publisher website ·
- Impact factor (publisher) 2025
- 3.5Publisher website ·
- CiteScore 2026-06
- 5.6LetPub ·
- CiteScore (publisher)
- 5.6Publisher website ·
- CiteScore (publisher) 2025
- 5.6Publisher website ·
- SJR 2026-06
- 1.05LetPub ·
- SNIP 2026-06
- 0.66LetPub ·
- h-index
- 88LetPub ·
- h-index
- 129OpenAlex ·
- i10-index
- 3,229OpenAlex ·
- 2-year mean citedness
- 3.15OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 24.19%LetPub ·
Volume
- Articles per year
- 134LetPub ·
- Articles per year (publisher) 2025
- 133Publisher website ·
- Downloads per year (publisher) 2025
- 282,717Publisher website ·
Articles by year OpenAlex count · 5,205 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 117 | 70 | 23 |
| 2025 | 164 | 76 | 314 |
| 2024 | 208 | 113 | 1,201 |
| 2023 | 182 | 112 | 1,501 |
| 2022 | 126 | 47 | 1,446 |
| 2021 | 121 | 45 | 1,734 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
124 daysMedian, submission to acceptance · P25–P75 85 days – 164 days
- Acceptance to online
- median 18 days (94 articles)
- Submission to online
- median 142 days
- Sample
- 94 articles with submission and acceptance dates (303 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 2 monthsLetPub ·
- Average acceptance (community reports)
- 50%LetPub ·
- Acceptance rate (publisher)
- 10%Publisher website ·
- Acceptance rate (publisher) 2025
- 10%Publisher website ·
- Submission to first decision
- 5 daysPublisher website ·
- Submission to first decision 2025
- 5 daysPublisher website ·
- Submission to acceptance 2025
- 106 daysPublisher website ·
- Acceptance to publication 2025
- 21 daysPublisher website ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,490 / EUR 3,780 / GBP 3,010 | — | — | |
| Publisher website | Yes, amount not published | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare2 items from the author guidelines
- Keywords
- ≤ 7
- Manuscript length
- ≤ 5,000 words
Article types accepted2, with length limits
- brief communicationave been specifically invited to do so. Brief communications should not exceed 2,500 words (this does not include the abstract and title.) They can remain text ≤ 2,500 words
- research papermarked equipment mentioned in the text. Research papers should not exceed 5,000 words within the main text. The figure limit is 7. Working Hypothmain text ≤ 5,000 words
Policy excerpts from the journal's websiteData availability, License & copyright, Open access
- Data availability Data Sharing and Data Accessibility
Data sharing expected; archive data in public repository Model summary
Please review Wiley’s policy here. This journal expects data sharing.
Source ↗Publisher website ·- License & copyright For authors signing the copyright transfer agreement
Copyright transfer agreement unless open access chosen Model summary
If the open access in hybrid titles option is not selected the corresponding author will be presented with the copyright transfer agreement (CTA) to sign. The terms and conditions of the CTA can be previewed in the samples associated with the Copyright FAQs below:
Source ↗Publisher website ·- Open access For authors choosing open access in hybrid titles
If the open access in hybrid titles option is selected the corresponding author will have a choice of the following Creative Commons License Open Access Agreements (OAA):
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Wiley-Liss Inc.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Monthly
- Founded
- 1988
- ISSN
- 0899-1987
- Electronic ISSN
- 1098-2744
- Latest issue on the website
- Volume 65, Issue 10 (October 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Molecular Carcinogenesis
What CAS zone is Molecular Carcinogenesis in?
In the 2025 upgraded edition of the CAS Journal Ranking, Molecular Carcinogenesis is in Zone 4 of Medicine, and in Zone 3 of the minor category Biochemistry & Molecular Biology / Oncology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Molecular Carcinogenesis?
The latest impact factor listed by LetPub is 3.5; CiteScore 5.6, h-index 129.
How long does peer review take at Molecular Carcinogenesis?
Based on the dates recorded on 94 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 124 days (interquartile range 85–164 days); authors report an average review time of about 2 months; the community-reported acceptance is “about 50%”; the journal's website gives an acceptance rate of 10% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Molecular Carcinogenesis?
According to the journal's author guidelines: Keywords: ≤ 7; Manuscript length: ≤ 5,000 words. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Which databases index Molecular Carcinogenesis?
According to LetPub and DOAJ records, Molecular Carcinogenesis is indexed in SCIE and Scopus.
Is Molecular Carcinogenesis open access, and what is the APC?
Molecular Carcinogenesis is a hybrid journal. For open-access publication: APC about USD 4,490.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .